VANGL2 and lung carcinoma: To the best of our knowledge, we have identified for the first time that circ‐IGF1R can inhibit the Wnt/β‐catenin pathway through the circ‐IGF1R–miR‐1270–VANGL2 axis in lung cancer, thereby inhibiting cell invasion and migration.